The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive treatment, …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background Several small studies on patients with COVID-19 and haematological
malignancies are available showing a high mortality in this population. The Italian Hematology …

Preliminary independent reports of the Italian GIMEMA and the Spanish PETHEMA trials for
newly diagnosed acute promyelocytic leukemia (APL) indicated a similarly high …

The clinical outcome of acute myeloid leukemia (AML) is extremely variable, ranging from
survival of a few days to cure. Different clinical and biological features at diagnosis have been …

Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific
gene expression. Altered chromatin function can lead to aberrant expression of growth …

Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal
tandem duplication (ITD) mutations of c-KIT, were observed in about 46% of core binding …

Thirty elderly (> 60 years) Philadelphia chromosome–positive (Ph + ) patients with acute
lymphoblastic leukemia (ALL) received imatinib, 800 mg daily, associated to steroids without …

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph +
acute lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 …

The GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN)
pretreatment on complete remission (CR) achievement and length, the influence of the …